106 related articles for article (PubMed ID: 18770646)
1. Flow cytometric FRET analysis of ErbB receptor tyrosine kinase interaction.
Diermeier-Daucher S; Brockhoff G
Curr Protoc Cytom; 2008 Jul; Chapter 12():Unit12.14. PubMed ID: 18770646
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
6. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.
Bowers G; Reardon D; Hewitt T; Dent P; Mikkelsen RB; Valerie K; Lammering G; Amir C; Schmidt-Ullrich RK
Oncogene; 2001 Mar; 20(11):1388-97. PubMed ID: 11313882
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET).
Lopez-Crapez E; Ho-Pun-Cheung A; Garnero P; Bazin H
Methods Mol Biol; 2015; 1233():45-55. PubMed ID: 25319888
[TBL] [Abstract][Full Text] [Related]
8. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
9. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements.
Nagy P; Bene L; Balázs M; Hyun WC; Lockett SJ; Chiang NY; Waldman F; Feuerstein BG; Damjanovich S; Szöllosi J
Cytometry; 1998 Jun; 32(2):120-31. PubMed ID: 9627225
[TBL] [Abstract][Full Text] [Related]
10. Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.
Szabó A; Horváth G; Szöllosi J; Nagy P
Biophys J; 2008 Aug; 95(4):2086-96. PubMed ID: 18487307
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis.
Diermeier-Daucher S; Hasmann M; Brockhoff G
Ann N Y Acad Sci; 2008; 1130():280-6. PubMed ID: 18596360
[TBL] [Abstract][Full Text] [Related]
12. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
14. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
15. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
16. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.
Contessa JN; Abell A; Valerie K; Lin PS; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):851-8. PubMed ID: 16751066
[TBL] [Abstract][Full Text] [Related]
17. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
[TBL] [Abstract][Full Text] [Related]
18. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
19. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
